Series A closed at $22 million  
Anti-infective biotechnology company Cempra Pharmaceuticals announced today that it has added Aisling Capital as an investor.

$14 Million Round of Financing 
Cempra Pharmaceuticals, announced today that it has closed a $14 million financing round.

Exclusive rights from Optimer Pharmaceuticals 
Optimer Pharmaceuticals has granted to Cempra exclusive worldwide rights